Multi-step vs. single-step resistance evolution under different drugs, pharmacokinetics and treatment regimens

  1. Claudia Igler  Is a corresponding author
  2. Jens Rolff
  3. Roland Regoes  Is a corresponding author
  1. ETH Zurich, Switzerland
  2. Freie Universität Berlin, Germany

Abstract

The success of antimicrobial treatment is threatened by the evolution of drug resistance. Population genetic models are an important tool in mitigating that threat. However, most such models consider resistance emergence via a single mutational step. Here, we assembled experimental evidence that drug resistance evolution follows two patterns: i) a single mutation, which provides a large resistance benefit, or ii) multiple mutations, each conferring a small benefit, which combine to yield high-level resistance. Using stochastic modeling we then investigated the consequences of these two patterns for treatment failure and population diversity under various treatments. We find that resistance evolution is substantially limited if more than two mutations are required and that the extent of this limitation depends on the combination of drug type and pharmacokinetic profile. Further, if multiple mutations are necessary, adaptive treatment, which only suppresses the bacterial population, delays treatment failure due to resistance for a longer time than aggressive treatment, which aims at eradication.

Data availability

All data and code generated or analysed during this study are included in the manuscript and supporting files. Source code has been provided for Figures 2-4, as well as S2-S17 in the form of an R package. Source data has been provided for Table 1, Figure 1B and S1.

The following previously published data sets were used
    1. Melnyk A
    2. Wong A
    3. Kassen R
    (2015) The fitness costs of antibiotic resistance mutations
    Dryad Digital Repository: http://doi.org/10.5061/dryad.5rc47.

Article and author information

Author details

  1. Claudia Igler

    Theoretical Biology, ETH Zurich, Zurich, Switzerland
    For correspondence
    claudia.igler@env.ethz.ch
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7777-546X
  2. Jens Rolff

    Institute for Biology, Freie Universität Berlin, Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1529-5409
  3. Roland Regoes

    Institute of Integrative Biology, ETH Zurich, Zurich, Switzerland
    For correspondence
    roland.regoes@env.ethz.ch
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8319-5293

Funding

Volkswagen Foundation (96517)

  • Claudia Igler
  • Jens Rolff
  • Roland Regoes

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2021, Igler et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,689
    views
  • 515
    downloads
  • 41
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Claudia Igler
  2. Jens Rolff
  3. Roland Regoes
(2021)
Multi-step vs. single-step resistance evolution under different drugs, pharmacokinetics and treatment regimens
eLife 10:e64116.
https://doi.org/10.7554/eLife.64116

Share this article

https://doi.org/10.7554/eLife.64116

Further reading

    1. Evolutionary Biology
    Mattias Siljestam, Claus Rueffler
    Research Article Updated

    The majority of highly polymorphic genes are related to immune functions and with over 100 alleles within a population, genes of the major histocompatibility complex (MHC) are the most polymorphic loci in vertebrates. How such extraordinary polymorphism arose and is maintained is controversial. One possibility is heterozygote advantage (HA), which can in principle maintain any number of alleles, but biologically explicit models based on this mechanism have so far failed to reliably predict the coexistence of significantly more than 10 alleles. We here present an eco-evolutionary model showing that evolution can result in the emergence and maintenance of more than 100 alleles under HA if the following two assumptions are fulfilled: first, pathogens are lethal in the absence of an appropriate immune defence; second, the effect of pathogens depends on host condition, with hosts in poorer condition being affected more strongly. Thus, our results show that HA can be a more potent force in explaining the extraordinary polymorphism found at MHC loci than currently recognised.

    1. Ecology
    2. Evolutionary Biology
    Rebecca D Tarvin, Jeffrey L Coleman ... Richard W Fitch
    Research Article

    Understanding the origins of novel, complex phenotypes is a major goal in evolutionary biology. Poison frogs of the family Dendrobatidae have evolved the novel ability to acquire alkaloids from their diet for chemical defense at least three times. However, taxon sampling for alkaloids has been biased towards colorful species, without similar attention paid to inconspicuous ones that are often assumed to be undefended. As a result, our understanding of how chemical defense evolved in this group is incomplete. Here, we provide new data showing that, in contrast to previous studies, species from each undefended poison frog clade have measurable yet low amounts of alkaloids. We confirm that undefended dendrobatids regularly consume mites and ants, which are known sources of alkaloids. Thus, our data suggest that diet is insufficient to explain the defended phenotype. Our data support the existence of a phenotypic intermediate between toxin consumption and sequestration — passive accumulation — that differs from sequestration in that it involves no derived forms of transport and storage mechanisms yet results in low levels of toxin accumulation. We discuss the concept of passive accumulation and its potential role in the origin of chemical defenses in poison frogs and other toxin-sequestering organisms. In light of ideas from pharmacokinetics, we incorporate new and old data from poison frogs into an evolutionary model that could help explain the origins of acquired chemical defenses in animals and provide insight into the molecular processes that govern the fate of ingested toxins.